Verona Pharma PLC ADR

Yahoo Finance • 9 days ago

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, A... Full story

Yahoo Finance • 27 days ago

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA... Full story

Yahoo Finance • 2 months ago

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Oht... Full story

Yahoo Finance • 2 months ago

Verona Pharma Announces March 2025 Investor Conference Participation

LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:... Full story

Yahoo Finance • 2 months ago

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2... Full story

Yahoo Finance • last year

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Verona Pharma plc Strengthens financial flexibility to support the Company’s continued growth LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-own... Full story

Yahoo Finance • last year

3 Stocks That Could Be Monster Winners in 2024

Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task. Three Motley Fool contributors think they've identified stocks that could be... Full story

Yahoo Finance • last year

Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023’ at the SCRIP Awards... Full story

Yahoo Finance • last year

11 Best Undervalued UK Stocks To Buy Now

In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now. If you want to skip our overview of the British economy, then take a look at 5 Best Undervalued UK Stocks To Buy Now. The U.K. is one of the biggest eco... Full story

Yahoo Finance • last year

Ligand Reports Third Quarter 2023 Financial Results

Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today SAN DIEGO, November 08, 2023--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporate... Full story

Yahoo Finance • last year

Verona Pharma Announces November 2023 Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the following conferences in November 20... Full story

Yahoo Finance • last year

Insider Sell: Chief Medical Officer Kathleen Rickard Sells 58,752 Shares of Verona Pharma PLC

On November 3, 2023, Kathleen Rickard, the Chief Medical Officer of Verona Pharma PLC (NASDAQ:VRNA), sold 58,752 shares of the company. This move is part of a series of transactions made by the insider over the past year, which have seen a... Full story

Yahoo Finance • last year

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference call today at 9:00 a.m. EDT / 1:00 p.m.... Full story

Yahoo Finance • 2 years ago

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report it... Full story

Yahoo Finance • 2 years ago

Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023

LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold an Investor Update in New York City for investors and analysts on Wednesday, October... Full story

Yahoo Finance • 2 years ago

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Oct. 03, 2023 (GLOBE... Full story

Yahoo Finance • 2 years ago

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade LONDON and RALEIGH, N.C., Sept. 11, 2023 (GLOBE NEWS... Full story

Yahoo Finance • 2 years ago

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

LONDON and RALEIGH, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces an oral presentation on an additional analysis from its successful Phase 3 ENHANCE-1 study with e... Full story

Yahoo Finance • 2 years ago

Christina Ackermann Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a Non-Executive Director. Ms. Ackerman... Full story

Yahoo Finance • 2 years ago

Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine

LONDON and RALEIGH, N.C., June 28, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the American Journal of Respiratory and Critical Care Medicine (“AJRCCM”) has published results fr... Full story